参考文献/References:
[1]Holgate ST.Immune circuits in asthma[J].Curr Opin Pharmacol,2013,13(3):345-350.
[2]Kim Y,Lee S,Kim YS,et al.Regulation of Th1/Th2 cellsin asthma development:a mathematical model[J].Math Biosci Eng,2013,10(4):1095-1133.
[3]Passalacqua G,Bagnasco D,Ferrando M,et al.Current insights in allergen immunotherapy[J].Ann Allergy Asthma Immunol,2018,120(2):152-154.
[4]Froidure A,Mouthuy J,Durham SR,et al.Asthma phenotypes and IgE responses[J].Eur Respir J,2016,47(1):304-319.
[5]Kuhl K,Hanania NA.Targeting IgE in asthma[J].Curr Opin Pulm Med,2012,18(1):1-5.
[6]Chen S,Golam S,Myers J,et al.Systematic literature review of the clinical,humanistic,and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment[J].Curr Med Res,2018,34(12):2075-2088.
[7]Pelaia G,Canonica GW,Matucci A,et al.Targeted therapy in severe asthma today:focus on immunoglobulin E[J].Drug Des Devel Ther,2017(11):1979-1987.
[8]Minami D,Kayatani H,Sato K,et al.Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab[J].Respirol Case Rep,2019,7(1):e00388.
[9]Corren J,Kavati A,Ortiz B,et al.Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma:A systematic literature review[J].Allergy Asthma Proc,2017,38(4):250-263.
[10]王刚,王曾礼.哮喘发病机制中IgE调控及重组人抗IgE单克隆抗体的应用[J].中华结核与呼吸杂志,2003,26(7):427-430.
[11]Pilon D,Kavati A,Ortiz B,et al.Asthma control,lung function,symptoms,and corticosteroid sparing after omalizumab?initiation in patients with allergic asthma[J].Allergy Asthma Proc,2018,39(2):127-135.
[12]Di DB,Fiorino I,Taurino M,et al.Long-term"real-life"safety of omalizumab in patients with severe uncontrolled asthma:A nine-year study[J].Respiratory Medicine,2017(130):55.
[13]Korn S,Thielen A,Seyfried S,et al.Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany[J].Respiratory Medicine,2009,103(11):1725-1731.
[14]Grimaldi-Bensouda L,Zureik M,Aubier M,et al.Does omalizumab make a difference to the real-life treatment of asthma exacerbations?Results from a large cohort of patients with severe uncontrolled asthma[J].Chest,2013,143(2):398-405.
[15]Jiang XG,Yang XD,Lv Z,et al.Elevated serum levels of TNF-α,IL-8,and ECP can be involved in the development and progression of bronchial asthma[J].Asthma,2018,55(2):111-118.
[16]Brown SD.Brown LA.Stephenson S,et al.Characterization of a high TNF-α phenotype in children with moderate-to-severe asthma[J].J Allergy Clin Immunol,2015,135(6):1651-1654.
[17]Taillé C,Poulet C,Marchand-Adam S,et al.Monoclonal Anti-TNF-αAntibodies for Severe Steroid-Dependent Asthma:A Case Series[J].Open Respir Med J,2013(7): 21-25.
[18]Huang H,Nie W,Qian J,et al.Effects of TNF-α polymorphisms on asthma risk:a systematic review and meta-analysis[J].Investig Allergol Clin Immunol,2014,24(6):406-417.
[19]Menzella F,Lusuardi M,Galeone C,et al.Tailored therapy for severe asthma[J].Multidiscip Respir Med,2015,10(1):1-8.
[20]Patel SS,Casale TB,Cardet JC.Biological therapies for eosinophilic asthma[J].Expert Opin Biol Ther,2018,18(7):747-754.
[21]Barnes PJ.Targeting cytokines to treat asthma and chronic obstructive pulmonary disease[J].Nat Rev Immunol,2018,18(7):454-466.
[22]Bagnasco D,Ferrando M,Varricchi G,et al.A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma[J].Int Arch Allergy Immunol,2016,170(2):122-131.
[23]Majumdar S,Ghosh A,Saha S.Modulating Interleukins and their receptors interactions with small chemicals using in silico approach for asthma[J].Curr Top Med Chem,2018,18(13):1123-1134.
[24]Walsh GM.Anti-IL-4/-13 based therapy in asthma[J].Expert Opin Emerg Drugs,2015,20(3):349-352.
[25]Lim HF,Nair P.Airway inflammation and inflammatory biomarkers[J].Semin Respir Crit Care Med,2018,39(1):56-63.
[26]Strauss RA,Jawhari N.Mepolizumab in the treatment of severe eosinophilic asthma:"results from a physician in the field"[J].Ann Allergy Asthma Immunol,2018,121(1):121-123.
[27]He LL,Zhang L,Jiang L.Efficacy and safety of anti-interleukin-5 therapy in patients with asthma:A pairwise and Bayesian network meta-analysis[J].Int Immunopharmacol,2018(64):223-231.
[28]Tung HY,Li E,Landers C,et al.Advances and Evolving Concepts in Allergic Asthma[J].Semin Respir Crit Care Med,2018,39(1):64-81.
[29]Parulekar AD,Kao CC,Diamant Z,et al.Targeting the interleukin-4 and interleukin-13 pathways in severe asthma:current knowledge and future needs[J].Curr Opin Pulm Med,2018,24(1):50-55.
[30]Seibold MA.Interleukin-13 Stimulation Reveals the Cellular and Functional Plasticity of the Airway Epithelium[J].Ann Am Thorac Soc,2018,15(Supplement_2): S98-S102.
[31]Devos FC,Pollaris L,Cremer J,et al.IL-13 is a central mediator of chemical-induced airway hyperreactivity in mice[J].PLoS One,2017,12(7):e0180690.
[32]Lamour S,Bourne T,Shaw S,et al.Efficacy of an Inhaled IL-13 antibody fragment in a model of chronic asthma[J].Am J Respir Crit Care Med,2018,198(5):610-619.
[33]Bopp T,Taube C.IL-10 and regulatory T cells cooperate in allergen-specific immunotherapy to ameliorate allergic asthma[J].J Immunol,2015,194(3): 887-897.
[34]B?觟hm L,Maxeiner J,Meyer-Martin H,et al.IL-10?and regulatory T cells cooperate in allergen-specific immunotherapy to ameliorate allergic asthma[J].J Immunol,2015,194(3):887-97.
[35]Girodet PO,Nguyen D,Mancini JD,et al.Alternative Macrophage Activation Is Increased in Asthma[J].Am J Respir Cell Mol Biol,2016,55(4):467-475.
[36]Vissers JL,van Esch BC,Hofman GA,et al.Allergen immunotherapy induces a suppressive memory response mediated by IL-10 in a mouse asthma model[J].J Allergy Clin Immunol,2004,113(6):1204-1210.
[37]Kuribayashi K,Kodama T,Okamara H,et al.Effects of post-inhalation treatment with interleukin-12 on airway hyper-reactivity,eosinophilia and interleukin-18 receptor expression ina mouse model of asthma[J].Clin Exp Allergy,2002(32):641-649.
[38]Zhou E,Fu Y,Wei Z,et al.Inhibition of allergic airway inflammation through the blockage of NF-κB activation by ellagic acid in an ovalbumin-induced mouse asthma model[J].Food Funct,2014,5(9):2106-2112.
[39]Bakkourik E,Wullaert A,Haegman M,et al.Adenoviral gene transfer of the NF-κB inhibitory protein abin-1 decreases allergic airway inflammation in a murine asthma model[J].J Biol Chem,2005,280(18):17938-17944.
[40]Krishnamurthy P,Kaplan MH.STAT6 and PARP Family Members in the Development of T Cell-dependent Allergic Inflammation[J].Immune Netw,2016,16(4):201-210.
[41]Mc Cracken JL,Veeranki SP,Ameredes BT,et al.Diagnosis and Management of Asthma in Adults: A Review [J].JAMA,2017,318(3):279-290.
[42]Rayees S,Malik F,Bukhari SI,et al.Linking GATA-3 and interleukin-13:implications in asthma[J].Inflamm Res,2014,63(4):255-265.
相似文献/References:
[1]焦龙龙,郭悦鹏.初诊哮喘患者的呼出气一氧化氮与大小气道功能的
相关性及临床价值分析[J].医学信息,2018,31(06):70.[doi:10.3969/j.issn.1006-1959.2018.06.022]
JIAO Long-long,GUO Yue-peng.Correlation and Clinical Value Analysis of Exhaled Nitric Oxide and Airway Function in Patients with Newly Diagnosed Asthma[J].Medical Information,2018,31(05):70.[doi:10.3969/j.issn.1006-1959.2018.06.022]
[2]刘玉振.孟鲁司特治疗支气管哮喘的临床研究[J].医学信息,2018,31(10):140.[doi:10.3969/j.issn.1006-1959.2018.10.047]
LIU Yu-zhen.Clinical Study of Montelukast in the Treatment of Bronchial Asthma[J].Medical Information,2018,31(05):140.[doi:10.3969/j.issn.1006-1959.2018.10.047]
[3]井庆彦.治未病三伏贴对支气管哮喘缓解期患者
冬病夏治的疗效观察[J].医学信息,2018,31(17):143.[doi:10.3969/j.issn.1006-1959.2018.17.045]
JING Qing-yan.Therapeutic Effect of Preventive Treatment of Disease of Sanfu Paster on Summer Treatment of Winter Disease in Patients with Bronchial Asthma[J].Medical Information,2018,31(05):143.[doi:10.3969/j.issn.1006-1959.2018.17.045]
[4]赵 静,陈华琴,张 宁,等.血清骨膜蛋白和脂联素联检诊断儿童支气管哮喘价值研究[J].医学信息,2018,31(21):71.[doi:10.3969/j.issn.1006-1959.2018.21.019]
ZHAO Jing,CHEN Hua-qin,ZHANG Ning,et al.Diagnostic Value of Serum Periosteal Protein and Adiponectin in Children with Bronchial Asthma[J].Medical Information,2018,31(05):71.[doi:10.3969/j.issn.1006-1959.2018.21.019]
[5]孟琳非,黄伟健,酆孟洁,等.基于聚类分析对慢性肺部疾病表型的研究进展[J].医学信息,2019,32(07):44.[doi:10.3969/j.issn.1006-1959.2019.07.015]
MENG Lin-fei,HUANG Wei-jian,FENG Meng-jie,et al.Advances in Research on Phenotypes of Chronic Lung Diseases Based on Cluster Analysis[J].Medical Information,2019,32(05):44.[doi:10.3969/j.issn.1006-1959.2019.07.015]
[6]韦春峥,莫 彬,莫善圆,等.孟鲁司特钠联合布地奈德治疗儿童支气管哮喘合并变应性鼻炎的临床效果[J].医学信息,2019,32(20):142.[doi:10.3969/j.issn.1006-1959.2019.20.044]
WEI Chun-zheng,MO Bin,MO Shan-yuan,et al.Clinical Effect of Montelukast Sodium Combined with Budesonide in the Treatment of Children with Bronchial Asthma Complicated with Allergic Rhinitis[J].Medical Information,2019,32(05):142.[doi:10.3969/j.issn.1006-1959.2019.20.044]
[7]易晓明,彭小娜.氧气驱动雾化吸入对支气管哮喘患者肺功能及血氧饱和度的影响[J].医学信息,2019,32(23):110.[doi:10.3969/j.issn.1006-1959.2019.23.030]
YI Xiao-ming,PENG Xiao-na.Effect of Oxygen-Driven Aerosol Inhalation on Lung Function and Oxygen Saturation in Patients with Bronchial Asthma[J].Medical Information,2019,32(05):110.[doi:10.3969/j.issn.1006-1959.2019.23.030]
[8]王启龙,张 蔚.支气管哮喘急性发作并肺部感染患者血清炎性因子、免疫球蛋白水平与预后的相关性分析[J].医学信息,2021,34(22):81.[doi:10.3969/j.issn.1006-1959.2021.22.024]
WANG Qi-long,ZHANG Wei.Correlation Analysis of Serum Inflammatory Factors, Immunoglobulin Levels and Prognosis in Patients with Acute Exacerbation of Bronchial Asthma Complicated with Pulmonary Infection[J].Medical Information,2021,34(05):81.[doi:10.3969/j.issn.1006-1959.2021.22.024]
[9]丁晓燕,丁惠芳.支气管哮喘患儿缓解期呼出气一氧化氮水平与肺功能的相关性研究[J].医学信息,2021,34(24):68.[doi:10.3969/j.issn.1006-1959.2021.24.014]
DING Xiao-yan,DING Hui-fang.Correlation Between Respiratory Nitric Oxide Level and Lung Function in Children with Bronchial Asthma During Remission Period[J].Medical Information,2021,34(05):68.[doi:10.3969/j.issn.1006-1959.2021.24.014]
[10]杨一民,黄小玲,李 溦,等.LTA4H基因多态性对汉族儿童支气管哮喘患者使用孟鲁司特钠疗效及肺功能的影响[J].医学信息,2022,35(20):49.[doi:10.3969/j.issn.1006-1959.2022.20.011]
YANG Yi-min,HUANG Xiao-ling,LI Wei,et al.Effect of LTA4H Gene Polymorphism on the Efficacy and Lung Function of Montelukast Sodium in Chinese Han Children with Bronchial Asthma[J].Medical Information,2022,35(05):49.[doi:10.3969/j.issn.1006-1959.2022.20.011]